Descending thoracic aorta to bifemoral bypass grafting in Aortobiiliac occlusive disease
Main Article Content
Abstract
Introduction: The aim of this prospective study is to describe the clinical symptoms, investigation findings and surgical treatment of aortoiliac occlusive disease where abdominal approach not feasible or not possible for aortobifemoral bypass grafting.
Method: From May 2013 to May 2019, ten patients were treated with descending thoracic aorto-bifemoral bypass for aortoiliac occlusive disease at Grant Medical College and JJ group of Hospitals, Mumbai (Maharashtra). Total 20 limbs were re-vascularized. Demographic data, co-morbid factors, per operative findings were noted. Indication for surgery is juxtarenal occlusion of the abdominal aorta, in most of the cases. In postoperative period, all patients were evaluated for appearance of distal pulsations, primary patency, warmness of foot, symptom relief, wound infection, healing of the ulcer, and complications. CT angiography was done in follow-up. Maximal followup of two years and minimum followup of one month was done after surgery.
Results: No mortality. Mean duration of surgery was 2.5-5 h and mean blood loss was 250 - 400 mL. Major morbidity includes one graft occlusion. None of the patients developed proximal propagation of aortic thrombus. Ulcers showed healing. All patients had a good quality of life postoperatively. Postoperative angiography showed good re-vascularization.
Conclusion: Majority of our patients are old age having juxtarenal aortic occlusion so we decided to use DTA as inflow for primary revascularization to avoid entering abdomen and renal injury. Some authors have recommended supraceliac aorta bypass surgery within the retroperitoneal space for juxtarenal aortic occlusive disease but is technically difficult and associated with morbidity. The major limitation to thoracic aorta bifemoral grafting technique is the morbidity rate associated with thoracotomy in a relatively high-risk vascular surgery population. Also, tunnelling in conventional DTA-to-femoral artery bypass is usually a “blind” procedure.For the cardiothoracic surgeon with experience, the use of descending thoracic aorta could be a very good alternative for infrarenal aortic occlusion or extra-anatomic aortoiliac bypass without any morbidity and mortality with good improvement in quality of life.
Downloads
Article Details
Copyright (c) 2020 Nagre SW.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Kasap S, Gonenc A, Sener DE, Hisar I (2007) Serum Cardiac Markers in Patients with Acute Myocardial Infarction: Oxidative Stress, C-reactive protein and N-terminal probrain natriuretic peptide. J Clin Biochem Nutr 41: 50-57. Link: https://bit.ly/3bbgwHx
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, et al. (2018) Fourth Universal Definition of Myocardial Infarction. J Am Coll Cardiol 72: 2231-2264. Link: https://bit.ly/2EOm1QA
Gupta S, Alagona P (2008) Troponins: not always a myocardial infarction. Am J Med 121: e25. Link: https://bit.ly/3gNuLU5
Chen Y, Tao Y, Zhang L, Xu W, Zhou X (2019) Diagnostic and prognostic value of biomarkersin acute myocardial infarction. Postgrad Med J 95: 210-216. Link: https://bit.ly/3bbVUis
Wu AH, Feng YJ, Contois JH, Pervaiz S (1996) Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction. Ann Clin Lab Sci 26: 291-300. Link: https://bit.ly/34Monu4
Nigam PK (2007) Biochemical markers of myocardial injury. Indian J Clin Biochem 22:10–17. Link: https://bit.ly/3gJa8Zo
Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, et al. (2013) High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol 62: 397-408. Link: https://bit.ly/31IMB6M
Hamzic Mehmedbasic A (2016) Inflammatory cytokines as risk factors for mortality after acute cardiac events. Med Arch 70: 252–255. Link: https://bit.ly/2ETtlKs
Wang J, Tang B, Liu X, Wang H, Xu D, et al. (2015) Increased monomeric CRP levels in acute myocardial infarction: a possible new and specific biomarker for diagnosis and severity assessment of disease. Atherosclerosis 239: 343-349. Link: https://bit.ly/31JdBCM
Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, et al. (1995) Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 41: 966-978. Link: https://bit.ly/2YRMYKm
Krause EG, Rabitzsch G, Noll F, Mair J, Puschendorf B (1996) Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Mol Cell Biochem 160: 289-295. Link: https://bit.ly/2EJohbH
Mair J (1997) Progress in myocardial damage detection: new biochemical markers for clinicians. Crit Rev Clin Lab Sci 34: 1-66. Link: https://bit.ly/3gM2mxM
Singh N, Rathore V, Mahat RK, Rastogi P (2018) Glycogen Phosphorylase BB: A more Sensitive and Specific Marker than Other Cardiac Markers for Early Diagnosis of Acute Myocardial Infarction. Ind J Clin Biochem 33: 356–360. Link: https://bit.ly/31JsGV7
Cubranic Z, Madzar Z, Matijevic S, Dvornik S, Fisic E, et al. (2012) Diagnostic accuracy of heart fatty acid binding protein (H-FABP) and glycogen phosphorylase isoenzyme BB (GPBB) in diagnosis of acute myocardial infarction in patients with acute coronary syndrome. Biochem Med (Zagreb) 22: 225-236. Link: https://bit.ly/3lxCvgC
Bozkurt S, Kaya EB, Okutucu S, Aytemir K, Coskun F, et al. (2011) The diagnostic and prognostic value of first hour glycogen phosphorylase isoenzyme BB level in acute coronary syndrome. Cardiol J 18: 496–502. Link: https://bit.ly/2YO4dvY
Serdar Z, Altin A, Serdar A, Bilgili G, Sarandol E, et al. (2012) Glycogen phosphorylase isoenzyme BB in early diagnosis of acute coronary syndrome. Nobel Medicus 8: 65-72. Link: https://bit.ly/2DdNGKh
Lillpopp L, Tzikas S, Ojeda F, Munzel T, Blakenberg S, et al. (2012) Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome. Am J Cardiol 110:1225-1230. Link: https://bit.ly/2EP8J6p
Peetz D, Post F, Schinzel H, Schweigert R, Schollmayer C, et al. (2005) Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 43:1351-1358. Link: https://bit.ly/3biUnY8
Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ (2004) Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 42: 121-131. Link: https://bit.ly/32yzOCM
Wang XH, Liu SQ, Wang YL, Jin Y (2014) Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome. Genet Mol Res 13: 4260-4266. Link: https://bit.ly/3lvDu0V
Acharya A, Sahu JK, Sharma SK, Mandal MK (2017) Serial Measurement of High Sensitive C Reactive Protein Levels of Patients Having Acute Chest Pain –Study in a Tertiary Care Centre of Western Odisha. JMSCR 5: 20243-20246. Link: https://bit.ly/3juwCz7
Basha SJ, Anil Kumar M, Lakshmi Prasad KK (2016) Role of HSCRP in Detecting Myocardial Infarction. IOSR-JDMS 15: 19-22.
Badiger RH, Dinesha V, Hosalli A, Ashwin SP (2014) hsC-reactive protein as an indicator for prognosis in acute myocardial infarction. J Sci Soc 41: 118-121. Link: https://bit.ly/3lFXLRJ
Aseri ZA, Habib SS, Alhomida SA, Khan HA (2014) Relationship of high sensitivity C-reactive protein with cardiac biomarkers in patients presenting with acute coronary syndrome. J Coll Physicians Surg Pak 24: 387-391. Link: https://bit.ly/2EFYGkf
Rathore V, Singh N, Rastogi P, Mahat RK (2017) Correlation of inflammatory marker with glycogen phosphorylase BB (GPBB) in patients of acute myocardial infarction. International Journal of Contemporary Medical Research 4: 1122-1124. Link: https://bit.ly/32UjeOf